In the following video, Motley Fool health care analyst David Williamson talks about Pfizer's (PFE) earnings report. He details how the company managed to cut costs and shore up emerging market sales -- leading to it beating expectations this quarter -- despite the loss of patent protection for its cardiovascular disease prevention drug Lipitor, which was once the greatest-selling drug of all time.